---
document_datetime: 2025-03-07 12:05:12
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/brinavess-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: brinavess-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.4060497
conversion_datetime: 2025-12-24 05:37:46.124057
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Brinavess

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0044               | Transfer of Marketing Authorisation                                                                                        | 29/11/2024                          | 19/12/2024                                  | SmPC, Labelling and PL           |           |
| IAIN/0043            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 18/10/2023                          | 01/10/2024                                  | Annex II and PL                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0042            | B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                                     | 14/09/2023   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/3109/ 202208 | Periodic Safety Update EU Single assessment - vernakalant hydrochloride                                                                                                                                                                                      | 14/04/2023   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| N/0040             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 02/03/2022   | 01/10/2024 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0039            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                | 07/07/2020   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| R/0037             | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 26/03/2020   | 02/06/2020 |                                  | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of Brinavess in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity. |
| PSUSA/3109/ 201908 | Periodic Safety Update EU Single assessment - vernakalant hydrochloride                                                                                                                                                                                      | 17/04/2020   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0035            | Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information following updates to the Company Core Safety Datasheet (CCDS) based on the results of an integrated safety analysis performed on data of existing clinical studies. The | 31/10/2019   | 02/06/2020 | SmPC, Annex II, Labelling and PL | Sections 4.4 and 4.8 of the Summary of Product characteristics (SmPC) is being updated following updates to the Company Core Safety Datasheet (CCDS) based on the results of an integrated safety analysis performed on data of existing clinical studies with a stronger emphasis on                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | Package Leaflet was updated accordingly. Update of the RMP to version 7.0 to incorporate the results from the new safety analysis and from the non-interventional PASS SPECTRUM study, listed as a category 3 study in the RMP (PASS Protocol 6621- 049). Update of sections 4.2, 4.4, 4.6, 4.7, 4.8, 5.1, 5.2, 5.3, 6.4 of the SmPC, Annex II, Labelling and Package Leaflet to include editorial changes, to correct typographical errors and to bring the PI in line with the latest QRD template version 10 and well as to update statements related to the excipients in the SmPC and Package Leaflet in line with the EC Guideline (SANTE-2017-11668). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                       | treatment-related ADRs and an incidence rate above one percent. The warnings regarding hypotension, congestive heart failure, atrial flutter and valvular heart disease were modified in section 4.4 of the SmPC and adverse events 'headache', 'chest discomfort' and 'ECQ QT prolonged' were removed from section 4.8 of the SmPC. These changes were considered consistent with the pooled trial data in the updated summary of clinical safety. The PL has been updated accordingly.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 19/09/2019 | 02/06/2020 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0036/G | This was an application for a group of variations. B.I.c.z - Container closure system of the AS - Other variation B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10/09/2019 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | a Member State - Excipient/AS starting material                                                                                                                                                                                                                      |            |            |                        |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| N/0033             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                     | 13/12/2018 | 02/06/2020 | Labelling              |                                   |
| IA/0032            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                         | 10/12/2018 | n/a        |                        |                                   |
| T/0031             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                  | 13/07/2018 | 08/08/2018 | SmPC, Labelling and PL |                                   |
| IA/0030            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                     | 18/05/2018 | n/a        |                        |                                   |
| PSUSA/3109/ 201708 | Periodic Safety Update EU Single assessment - vernakalant hydrochloride                                                                                                                                                                                              | 12/04/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0029/G          | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 09/01/2018 | 08/08/2018 | SmPC                   |                                   |
| N/0027             | Minor change in labelling or package leaflet not                                                                                                                                                                                                                     | 07/06/2017 | 08/08/2018 | Labelling              |                                   |

<div style=\"page-break-after: always\"></div>

|                    | connected with the SPC (Art. 61.3 Notification)                                                                                                                        |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/3109/ 201608 | Periodic Safety Update EU Single assessment - vernakalant hydrochloride                                                                                                | 09/03/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0025             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                       | 12/09/2016 | 08/08/2018 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/3109/ 201508 | Periodic Safety Update EU Single assessment - vernakalant hydrochloride                                                                                                | 17/03/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0023             | Renewal of the marketing authorisation.                                                                                                                                | 21/05/2015 | 28/07/2015 | SmPC                   | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Brinavess continues to be favourable. The CHMP was of the opinion that an additional five-year renewal on the basis of pharmacovigilance grounds was required. |
| PSUSA/3109/ 201408 | Periodic Safety Update EU Single assessment - vernakalant hydrochloride                                                                                                | 26/03/2015 | 27/05/2015 | SmPC                   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3109/201408.                                                                                                                                                                                                                                                                                            |
| IB/0021            | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 01/12/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IAIN/0020          | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                             | 03/10/2014 | 28/11/2014 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUV/0019   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                       | 10/04/2014   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                             |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                    | 15/11/2013   | 28/11/2014 | SmPC                             |                                                                                                                                                                                                                                               |
| IAIN/0017/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/11/2013   | 28/11/2014 | Annex II and PL                  |                                                                                                                                                                                                                                               |
| IAIN/0016   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                              | 27/08/2013   | n/a        |                                  |                                                                                                                                                                                                                                               |
| T/0013      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                          | 24/05/2013   | 21/06/2013 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                               |
| II/0012     | Update of section 4.8 of the SmPC following the results of the ACT V study. The Package Leaflet was updated accordingly. In addition the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore the PI is being brought in line with the QRD template version 8.3.                                                                         | 25/04/2013   | 21/06/2013 | SmPC, Annex II, Labelling and PL | Section 4.8 of the SmPC was updated in order to provide additional information regarding the nature and frequency of adverse events (AEs) related to treatment with vernakalant IV based on the safety results from the ACT V clinical trial. |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0011/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                               | 26/10/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0009   | The MAH proposed the update of Section 4.2 of the SmPC, Annex II, IIIA and IIIB in order to include the information about the pre-infusion checklist as a new risk minimisation tool as a follow up to the CHMP's assessment of a case of fatal hypotension. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 19/07/2012 | 23/08/2012 | Annex II and Labelling | A case of fatal hypotension related to the use of vernakalant hydrochloride (VH) was provided regarding a patient with type 2 diabetes mellitus, hypertension, polymyalgia and a history of coronary artery disease. The available information was considered by the CHMP as insufficient to determine whether the patient was eligible for treatment. Therefore, the causality assessment remains inconclusive. Nevertheless the risk minimization tools will be enhanced and the Pre-Infusion check list will be included as part of the package at the time of administration. |
| IG/0182   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/08/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0008   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                           | 24/05/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0007   | Update of sections 4.2 and 4.4 of the SmPC in order to update the safety information related to the administration of vernakalant hydrochloride following the recommendations from the assessment of PSUR 005. As a consequence, the description of the educational material was updated. The Package Leaflet was updated in accordance. In addition, the MAH took the opportunity to propose small editorial changes in Sections 4.3, 4.4, 4.8 of the SmPC and in the Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the   | 16/02/2012   | 26/03/2012   | SmPC and PL   | Following the assessment of the last PSUR and in view of the case reports of hypotension and bradycardia that have been assessed it was proposed to update sections 4.2 and 4.4 of the SmPC to provide further guidance to the healthcare providers regarding the way patients should be monitored during and after administration of Brinavess. With current variation the information was introduced that patient should be frequently monitored for the duration of the infusion of Brinavess and for at least 15 minutes after the completion of the infusion for signs and symptoms of a sudden decrease in blood pressure or heart rate.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0006/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/12/2011   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/12/2011   | 26/03/2012   | PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IG/0112   | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                      | 11/10/2011   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002   | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 17/02/2011   | 14/04/2011 | SmPC, Annex II and PL | Since vernakalant was licensed in September 2010, a serious adverse event of severe hypotension and subsequent cardiogenic shock has been reported in a patient receiving i.v. vernakalant in an ongoing clinical study (ACT V). Shortly after the infusion was completed, the patient developed hypotension with cardiac arrest and pulseless electrical activity. A complicated and prolonged resuscitation involving electrical defibrillation and the use of DC cardioversion and amiodarone followed. The patient developed multi-organ failure and passed away 28 days after the initial event. Following the assessment of the information related to this serious case the CHMP recommended modification of the SmPC. Close monitoring of vital signs and continuous monitoring of cardiac rhythm during administration of vernakalant, and up to 2 hours after the start of infusion until clinical and ECG parameters have stabilised, is recommended. Blood pressure should also be monitored, both during vernakalant infusion and at least 15 minutes after the infusion is completed. Patients must not be given any i.v. anti-arrhythmic drugs (class I or class III) within 4 hours prior to, during or up to 4 hours after vernakalant administration. PL and the educational materials were updated to reflect the changes to the SmPC. |
| IG/0027/G | This was an application for a group of variations.                                                                                                                                                                                                          | 10/11/2010   | n/a        | Annex II              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|        | system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |     |                  |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------|
| N/0001 | The Marketing Authorisation Holder took the opportunity to update Annex III A following a mock- up review and also update details for a local representative in Annex IIIB. Minor change in labelling or package leaflet not                                                           | 29/09/2010 | n/a | Labelling and PL |